Otsuka’s Lupkynis (voclosporin) Receives NICE Recommendation for the Treatment of Active Lupus Nephritis
Shots:
- The NICE has recommended Lupkynis in combination with mycophenolate mofetil for use within NHS England & NHS Wales in adults with active LN class III, IV, or V
- The recommendation was based on the P-III study (AURORA 1 & 2) evaluating voclosporin + MMF & corticosteroids vs MMF & corticosteroids alone. The (AURORA 1) study results showed that 40.8% of patients with voclosporin vs 22.5% in PBO achieved superior renal responses @52wks., safety & AEs were assessed while (AURORA 2) study evaluated the long-term safety & efficacy for additional ~24mos. who completed treatment in (AURORA 1) study
- Under Dec 2020 agreement, Otsuka & Aurinia collaborated to develop & commercialize voclosporin for LN in the EU, Japan, the UK, Russia, Switzerland, Norway, Belarus, Iceland, Liechtenstein & Ukraine
Ref: Pharmiweb | Image: Otsuka
Related News:- Aurinia’s Lupkynis (voclosporin) Receives EC’s Approval for the Treatment of Lupus Nephritis
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at connect@pharmashots.com.
